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1. Introduction  
Bone tissue engineering using various cell sources and materials has become an intriguing 
field, aimed at solving the problem of treatment of numerous clinical indications requiring 
regeneration of damaged or deficitary bone.  
During the Paleozoic period, evolution produced the skeleton. This 500 million-year-old  
creation has the capacity for regeneration, a term which until recently has been  reserved to 
new tissue and organs formation as in hydra, planarians or salamanders (Braddock et al., 
2001). The regeneration of bone (or the stimulation of bone production) is often required to 
treat loss of bone tissue brought about by trauma, osteonecrosis and tumors. Among the 6 
millions fractures occurring every year in the United States, 5-10% are classified 
unfavorable, requiring further treatment due to compromised healing (Praemer et al., 1992). 
The clinical  and socioeconomic challenge of treatments of bone defects is staggering. For 
example, the number of total joint arthroplasties (TJAs) and revision surgeries in the US has 
increased from 700,000 in 1998 to over 1.1 million in 2005. Medical expenses relating to 
fracture, reattachment, and replacement of hip and knee joint was estimated to be over $20 
billion (USD) in 2003, and predicted to increase to over $74 (USD) billion by the year 2015. 
Similar trend is observed in spinal arthrodesis (reviewed in Porter et al, 2009).  
Bone tissue provides mechanical stability to the skeleton, which is needed for load bearing, 
locomotion and protection of internal organs. Furthermore, bone serves as a mineral 
reservoir and has the capacity rapidly to mobilize mineral stores if needed for homeostasis 
of the calcium blood level (Kneser et al., 2006).  
The functional integrity of bone tissue is maintained by three main different cell types: 
osteoblasts, osteocytes and osteoclasts, which are embedded in a highly complex matrix 
consisting of a mineralized (hydroxyapatite) and a non-mineralized component. The non-
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mineralized organic part contains mainly collagens (approx. 95%), the remaining organic 
component of 5% is composed of glycoproteins, proteoglycans and other numerous non-
collagenous proteins (Meyer and Wiesmann, 2006).  
Bone development and bone regeneration are complexly regulated processes that involve a 
plethora of different growth and transcription factors, which coordinate the interaction of 
cells and matrix in response to external or internal stimuli (Kneser et al., 2006). Bone 
metabolism involves the resorption of existing bone by osteoclasts and the subsequent 
formation of a new bone matrix by osteoblasts. These activities are essential for bone 
remodeling, regeneration and repair (DeLong et al., 2007).  
Various sources of cells (periosteal cells, cortical cells, cells derived from the surrounding 
soft tissues, and marrow cells) and signals that set up these fields are responsible for the 
features of the repair tissue. The primary tissue source of cells that form repair tissue is 
believed to be from the periosteum. Other cells that contribute to or repair tissue formation 
appear to be derived from the adjacent cortical and cancellous bone. Mesenchymal stem 
cells, assumed to be derived from either the surrounding muscle tissue or the marrow space, 
are a third source of cells that participate in the formation of new bone. Cells synthesize a 
network of collagnenous and non-collagenous proteins. The final stage of bone repair and 
regeneration is the establishment of mineralized, mechanically competent tissue. Collagens, 
as the major constituent of the extracellular matrix network, are of major importance in the 
formation of a mineralized matrix. (Nakahara et al., 1990; Meyer and Wiesmann, 2006) 
The healing potential of bone is sufficient to restore simple fractures, which are generally 
treated by standard conservative or surgical therapy. However, in some cases, reparative 
osteogenesis does not result in structural and functional recovery of the bone (Logeart-
Avramoglou et al., 2005). Extended bone defects following trauma or cancer resection or 
non-unions of fractures may require more sophisticated treatment. In these cases, bone 
grafting procedures, segmental bone transport, distraction osteogenesis or biomaterials are 
applied for reconstruction (Meyer and Wiesmann, 2006). The repair of bone defects in 
reconstructive surgery is subject to significant limitations, including donor site morbidity, 
limited supply of autograft, risk of infection and immune rejection of allograft, and poor 
osteogenic effect of synthetic bone substitutes (Logeart-Avramoglou et al., 2005). In addition, 
bridging of a large bone defect by callus distraction requires a long time and usually an 
external fixator, both very inconvenient for patients. Regardless of the technique used, the 
percentage of failure is considerable. Bone repair is therefore the subject of intensive 
investigation in reconstructive surgery. 
2. Treatment of bone defects 
The reconstruction of large bone defects is an important clinical problem and none of the 
approaches thus far have proved completely effective. Since there are major limitations 
when treating ”problematic” bone tissue defects according to standard protocols, there is a 
great need for the development of new approaches for reparative osteogenesis. There are a 
number of clinical indications, such as non-unions, benign bone lesions, parodontal bone 
lesions, traumatic injuries, which could benefit from advances made during the past decade 
in bone cell therapies and tissue engineering. Cell therapies involve the use of any kind of 
cells to repair damaged or destroyed bone cells or tissues, and are unique in that the active 
component consists of living cells.  
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One of the biggest cell therapy areas is tissue engineering, defined by Langer and Vacanti 
(1993) as an interdisciplinary field that applies the principles of engineering and the life 
sciences to the development of biological substitutes that restore, maintain or improve tissue 
function. Tissue can be engineered 1) in vivo - by stimulating the body's own regeneration 
response with the appropriate biomaterial, or 2) ex vivo - cells can be expanded in culture, 
attached to a scaffold and then reimplanted into the host. Depending on the source, cells 
may be heterologous (different species), allogeneic (same species, different individual) or 
autologous (same individual). Autologous cells are preferred because they will not evoke an 
immunologic response and the deleterious side effects of immunosuppressive agents can 
thus be avoided. In addition, the potential risks of pathogen transfer are also eliminated 
(Hipp and Atala, 2004).  
When engineering bone tissue substitutes, mechanical stability, osteoconductivity, 
osteoinductivity, osteogenicity and ease of handling have to be well balanced in order 
properly to meet clinical needs (Kneser et al., 2006). According to Muschler and co-workers 
(2004), there are four types of cell-based tissue engineering: (1) local targeting of connective 
tissue progenitors where new tissue is needed, (2) transplanting autogenous connective 
tissue progenitors to augment the local population, (3) transplanting culture expanded or 
modified connective tissue progenitors and (4) transplanting fully formed tissue.  
Osteogenic cells are an integral part of any bone tissue engineering strategy. These cells are 
either transplanted along with the appropriate scaffolds into the bone defects or attracted 
from the host by osteoinductive factors (Kneser et al., 2006). The affectors of bone 
remodeling, regeneration and fracture repair in an adult organism are the cellular 
components. Various types of osteogenic cells, including bone marrow mesenchymal stem 
cells (BMSC) (Frank et al., 2002; Meinel et al., 2004; Meinel et al., 2005), adipose-derived stem 
cells (ASC) (Lendeckel et al., 2004; Peterson et al., 2005) mesenchymal cells of the periosteum 
(Hutmacher and Sittinger, 2003; Schimming and Schmelzeisen, 2004, Turhani et al., 2005) 
and alveolar bone derived osteoblasts (AO) (Xiao et al., 2003; Zhu et al., 2006) have been 
studied for bone reconstruction. Pluripotent mesenchymal stem cells are present in many 
adult tissues, although they are most abundant in bone marrow (Pittenger et al., 1999) and 
adipose tissue (Zuk et al., 2001). In vitro, BMSC are rapidly adherent, clonogenic and capable 
of extended proliferation (Bianco et al., 2001).   Isolation and expansion efficiency, stability of 
osteoblastic phenotype, in vivo bone formation capacity and long-term safety are essential 
requirements that must be met by any type of osteogenic cell for successful clinical 
application. Serum-free culture conditions or culture medium supplemented with 
autologous serum are preferable for cell expansion in vitro (Kneser et al., 2006).  
Nevertheless, it has still not yet been determined which type of osteogenic cell is most 
suitable for engineering bone tissue. At the moment, BMSC seem to be the best candidate for 
cell therapy to regenerate injured skeletal tissues, owing to their ease of isolation, expansion 
and multilineage potential. These cells can be induced to differentiate into chondrocytes or 
osteoblasts when subjected to specific environmental factors (Jorgensen et al., 2004). Proof-
in-principle for bone tissue engineering using BMSC has been demonstrated in various 
animal models (for review see Cancedda et al., 2003); in addition, 7 human clinical studies 
had been conducted by 2010 (Chatterjea et al., 2010). However, several studies have also 
shown ASC and AO to be appropriate cell sources for bone regeneration (Zuk et al., 2001; 
Cowan et al., 2004; Hattori et al., 2006; Fröhlich et al., 2010; Turhani et al., 2005; Maličev et al., 
2008). 
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Bone tissue engineering requires not only living cells but also the use of scaffolds, which 
serve as a three-dimensional environment for the cells. Scaffolds for engineering bone 
should satisfy a number of criteria. According to Logeart-Avramoglou et al. (2005), such 
matrices should be: (i) biocompatible (non-immunogenic and non-toxic); (ii) absorbable 
(with rates of resorption commensurate with those of bone formation); (iii) preferably 
radiolucent (to allow the new bone to be distinguished radiographically from the 
implant); (iv) osteoconductive; (v) easy to manufacture and sterilize; and (vi) easy to 
handle in the operating theater, preferably without preparatory procedures (in order to 
limit the risk of infection). Three-dimensional scaffolds for bone tissue regeneration 
require an internal microarchitecture, specifically highly porous interconnected structures 
and a large surface-to-volume ratio, to promote cell in-growth and cell distribution 
throughout the matrix (Logeart-Avramoglou et al., 2005). Pore sizes in the range of 200-
900 µm have performed most satisfactorily in these applications because, in addition to 
osteoprogenitor cells, they also enable endothelial cells to migrate into the matrix and 
develop the vascular beds necessary to nourish the newly formed tissue (Logeart-
Avramoglou et al., 2005). Particle size, shape and surface roughness affect cellular 
adhesion, proliferation and phenotype. Specifically, cells are sensitive and responsive to 
the chemistry, topography and surface energy of the material substrates with which they 
interact. In this respect, the type, amount and conformation of specific proteins that 
adsorb onto material surfaces, subsequently modulate cell functions (Boyan et al., 1996). 
Calcium based ceramics undergo dissolution and precipitation at their surfaces. These 
events lead to the formation of a carbonate-containing hydroxyapatite layer, which 
promotes the attachment of bone forming cells (i.e., osteoconductivity) (Ohgushi et al., 
1999). Tricalcium phosphate (TCP) and hydroxyapatite (HA) are therefore most 
commonly used as a scaffold in bone tissue engineering. In addition, these two materials 
are commercially available from various producers (DeLong et al., 2007) and well accepted 
in clinical practice as synthetic substitutes (or bone fillers). 
In order to evaluate where is a niche for autologous cell therapy in medical practice, an 
overview of other established treatments is necessary. 
2.1 Estabished treatments of bone defects 
Orthopaedic trauma surgery requires the regular use of bone grafts to help provide timely 
healing of muscoskeletal injuries. The “perfect” bone graft has properties categorized as: 
osteoconductive, osteoinductive and osteogenic (De Long et al., 2007). Osteoconduction is 
the property of a matrix that supports the attachment of bone-forming cells for subsequent 
bone formation. Osteoinduction is a process that supports the mitogenesis of 
undifferentiated cells, leading to the formation of osteoprogenitor cells that form new bone. 
The terms “osteogenic“ and „osteogenesis“ may be reserved for  the ability to generate or 
the generation of bone by bone-forming cells. 
2.1.1 Bone grafts and substitutes   
Today, autologous bone grafting is the gold standard for osteogenic replacement in osseous 
defects (DeLong et al., 2007). Autologous bone grafts reliably fill substance deficits and 
induce bone tissue formation at the defect site following transplantation. These grafts 
exhibit some initial stability, depending on donor site, size, shape and quality (Kneser et al., 
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2006). However, the clinical use of autologous osseous transplants is limited by a 
considerable donor site morbidity, which increases with the amount of harvested bone. 
Bleeding, hematoma, infection and chronic pain are common complications of bone graft 
harvest (Ebraheim et al., 2001). In addition, when the bone defect is large, there may not be 
enough autologous bone tissue to harvest. Processed allogeneic or xenogenic bone grafts are 
also commonly used for repair of osseous defects when autologous transplantation is not 
appropriate (Gazdag et al., 1995). Although the initial properties of allogeneic or xenogenic 
grafts resemble those of autologous bone, the lack of osteogenicity is a limitation even when 
osteoinductive factors are preserved during processing. For specific indications, 
vascularized bone grafts from various locations, including fibula, scapula, iliac crest and 
others, are taken and transplanted into given bone defects (Ozaki et. al., 1997).  
2.1.2 Synthetic bone substitutes 
Degradable and non-degradable implant materials can be divided into synthetically 
produced metals and metallic alloys, ceramics, polymers and composites or modified 
natural materials (Mayer and Wiesmann, 2006). Whereas non-resorbable materials such as 
steel or titanium alloys are commonly used for prosthetic devices, resorbable substitute 
materials are currently being investigated for their use in bone and cartilage replacement 
therapies (Mayer and Wiesmann, 2006). Acrylate-based bone cements provide high 
mechanical stability after polymerization (Lewis, 1997). They are widely used for fixation 
of total joint prosthesis, vertebroplasty and for craniofacial bone defects. However, 
despite sophisticated modes of application, they do not possess osteogenic or 
osteoinductive properties and are slowly resorbed, if at all. Within the last two decades, 
many other biogenic and synthetic materials have been evaluated for their use as bone 
substitutes. Calcium phosphate- and apatite-based bone cements (porous composites and 
the most widespread ceramics used for bone reconstruction), as well as other types of 
biomaterials have been clinically applied for the treatment of fractures and bone defects 
(Jupiter et al., 1997). Depending on their chemical composition and porosity, they are 
osteoconductive, biodegradable and are integrated into given bone defects (Kneser et al., 
2006). 
2.2 Advanced approaches to treating bone defects 
2.2.1 Osteoinductive substances 
Although osteoinductive substances are clinically applied for the reconstruction of bone 
defects or for acceleration of fracture healing, only small numbers of patients have been 
treated and application modes and indications are not yet completely standardized. Platelet 
rich plasma contains, in addition to platelet derived growth factor (PDGF), a variety of 
different growth factors, depending on the processing and application modes andit 
enhances bone formation in experimental and clinical settings (Thornwarth et al., 2006). 
Demineralized bone matrix (DBM) is prepared from allogeneic or xenogenic bone and is 
commercially available for clinical application in various formulations (Maddox et al., 2000). 
Its osteoinductive potential is highly variable and depends not only on the donor but also on 
the processing protocols. DBM is commonly used in combination with other types of 
biomaterials. Bone morphogenetic proteins (BMPs) have been identified as the most relevant 
osteoinductive factor in demineralized bone matrix (Reddi et al., 1998).   
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2.2.2 Allogenic bone tissue engineering products used in clinical practice and trials 
The first registered tissue engineered bone product is called Osteocel, launched in the USA 
in July 2005 by Osiris Therapeutics Inc. It was the first product containing viable allogenic 
adult stem cells to be offered for the repair, replacement or reconstruction of bone defects. 
Osteocel promotes bone regeneration and is used to treat spinal defects or hard-to-heal 
fractures, in which the bone is shattered or pieces are missing. The producer declares this 
product to be the first bone matrix product to provide all three bone growth properties: 
osteoconduction, osteoinduction, and osteogenesis.  
Osteocel is made from mesenchymal stem cells, which are mixed with spongy bone material 
obtained from human donors or cadavers. Because the cells are not manipulated (only 
harvested, processed and stored for later use, much like organs used for transplant), 
Osteocel is classified by the Food and Drug Administration (FDA) as a tissue transplant, not 
as a drug or a medical device. This product did not therefore have to go through the 
multiyear testing and approval process, which would most likely be be required for other 
stem cell products being developed.. Osteocel is an allogeneic tissue engineered product, 
exhibiting low immunogenicity and no activation of lymphocytes T in mixed leukocyte 
reaction testing in vitro. Osteocel grafts have been used since 2005 in over 30,000 procedures, 
with no reported adverse events.  
Trinity™ by Blackstone Medical Inc. is another allograft substance that has recently begun 
to be used. Trinity BMSC are pre-immunodepleted and therefore do not stimulate local T-
cell proliferation but instead are activated to act as osteoblasts and to stimulate bone 
formation. This local response can accelerate healing, earlier weight-bearing, healing and 
filling of bone voids in patients that have had excision of bony masses. In previous animal 
models, the use of BMSC has been shown to increase bone healing in critical sized defects. 
Trinity is currently approved by the FDA for use in trauma and bone defects within the 
spine, and has not shown any significant adverse effects compared with standard bone 
substitute products. 
2.2.3 Autologous cell treatment approaches to bone defects 
A widely accepted approach is the use of autologous cells for bone regeneration, which are 
frequently prepared as in-hospital procedures or produced only for the local market. 
According to Chatterjea et al. (2010), 7 human clinical studies have so far been conducted 
based on the use of BMSC. 
In 2001, BioTissue Technologies AG launched a product called BioSeed®-Oral Bone, using 
periosteum samples as a source of cells with osteogenic potential. BioSeed®-Oral Bone is a 
3D jawbone graft used to reconstruct the jaw bone, for example in sinus lift operations or 
lower jaw augmentation. 
Aastrom Biosciences in the USA has produced bone regeneration products for the treatment 
of osteonecrosis of the femoral head (called the ON-CORE trial) and a product for the 
treatment of severe non-union fractures (i.e., atrophic non-unions), both of which are in 
Clinical Phase III of development. Bone Repair Cells (BRCs) were derived from a small 
sample of the patient's bone marrow that is processed using Aastrom's Tissue Repair Cell 
(TRC) Technology to generate larger numbers of stem and early progenitor cells with 
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enhanced therapeutic potential. In the study, patients underwent standard open reduction 
and internal fixation surgery, in which BRCs were applied directly to the fracture site, 
together with an allograft bone matrix, to promote local bone regeneration. After the 
treatment with BRCs, patients with non-union tibia, humerus or femur fractures that had 
previously failed to heal after one or more “standard” medical procedures showed an 
overall healing rate of 91% after one year. The positive results from this study, together with 
early clinical data reported from osteonecrosis patients, further support the broad 
application of the proprietary TRC Technology in the field of orthopedics. 
There have been several clinical reports about the treatment of critical-sized long bone 
defects with tissue engineering products using BMSC and scaffolds (Quarto et al., 2001, 
Orozco et al., 2005).   
Some ongoing clinical trials are testing the treatment of non-union fractures and bone cysts 
by autologous mesenchymal stem cell percutaneous grafting as a minimally invasive 
implantation procedure (ClinicalTrials.gov Identifier: NCT01429012; NCT01206179; 
NCT01207193; NCT00916981; NCT00916981). 
3. Testing different approaches for the production of autologous tissue 
engineered bone constructs  
Aspects that need to be considered in planning a cell therapy/tissue engineering approach 
are: 
- biological: cells to express adequate cell phenotype to produce bone tissue 
- tissue engineering: scaffold that allows cell survival, is biodegradable, non-
immunogenic, possesses appropriate biomechanical properties and is easy to handle 
- surgical: adaption to the size and shape of the injury, a good clinical outcome could be 
expected upon the appropriate selection of clinical indications 
Since 2005, we have been working on several bone tissue engineering projects employing 
various osteogenic cells:  
 Engineering bone grafts using AO and rotating bioreactor – in vitro study 
 Engineering bone grafts using BMSC- in vitro study 
 Engineering bone grafts using ASC and perfusion culture - in vitro study  
 Vascularization of tissue engineered bone grafts - in vitro study  
 BMSC based bone grafts for the repair of long bone defects - clinical project   
 Treatment of paradontal diseases with AO - clinical project  
3.1 In vitro investigation of osteogenic potential of different cell sources 
Various cell source, namely AO, BMSC, and ASCwere investigated in relation to different 
targeted clinical indications. The basic proof of osteogenic activity is mineralization of the 
extracellular matrix, which was found in all three investigated cell types. Additionally, 
specific gene expression and alkaline phosphatase activity was analyzed. 
While AO were investigated to treat small volume defects in periodontal intrabony defects, 
both BMSC and ASC can be obtained in sufficient number from bone marrow aspirate or 
liposuction and proliferated enough to treat high volume bone defects (up to 50 cm3) and 
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were studied in relation to the treatment of more extensive, e.g., long bone defects 
(pseudoarthrosis).  
ASC and BMSC were tested for the expression of mesenchymal stem cell markers and for 
their capacity for mineralization after osteogenic differentiation. All tested cells expressed 
markers of mesenchymal stem cells DG73, CD90 and CD105 and were negative for CD34, 
which is a marker of hematopoietic cells (Table 1). All tested cell types were also positive for 
mineralization, which occurred in cultures of alveolar osteoblasts after 1-2 weeks of 
cultivation in osteogenic medium and in cultures of both mesenchymal stem cell types after 
2-3 weeks of cultivation in osteogenic medium (Fig. 1). The intensity of matrix 
mineralization, however, significantly varied among cell cultures from different donors. 
 
Marker
Sample 
 
CD 105 
 
CD 90 
 
CD 73 
 
CD34 
BMSC 30 + +++ +++ --- 
BMSC 31 + +++ +++ --- 
BMSC 35 + +++ +++ --- 
ASC 01 (P3) + +++ +++ --- 
ASC 02 (P3) ++ +++ +++ --- 
ASC 03 (P3) + +++ +++ --- 
ASC 04 (P6) +++ +++ +++ --- 
Table 1. Expression of mesenchymal stem cell markers by BMSC and ASC 
 
 
 
Fig. 1. Mineralization of the matrix is occurring in cultures of AO (A), BMSC (B) and ASC 
(C) after induction of osteogenic differentiation (upper line: culture in normal medium, 
bottom line: cultures in osteogenic medium). Von Kossa staining. (photos were taken at a 
magnification of 100x).  
3.1.1 Engineering bone grafts using Alveolar Osteoblasts (AO) and a rotating 
bioreactor 
AO can be isolated from alveolar bone tissue that is normally discarded prior to treatment of 
periodontal diseases. The use of alveolar bone tissue as a cell source for periodontal 
       A                B        C 
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indications therefore represents no additional harm to the patient and is thus considered to 
be the optimal cell source for this application. 
The aim of this study was to engineer bone grafts using AO for treating bone degeneration 
in periodontal diseases. 
After harvesting a piece (approx. 40 mm3) of maxillar or mandibular alveolar bone, primary 
explant culture and subsequently cell cultures of the first passage were established (Fig. 2).  
 
Fig. 2. Primary explant culture (left) and the first passage (right) of AO cells for the 
treatment of periodontitis (photos were taken at magnification 100x).  
Expanded AO with proven osteogenic potential were loaded onto macroporous 
hydroxyapatite granules together with fibrin glue, which enabled the formation of solid 
grafts (Fig. 3), and cultured in medium supplemented with osteogenic differentiation factors 
for up to three weeks in a rotating bioreactor. Light and scanning electron microscopic 
examinations of the cell-seeded constructs showed a uniform cell distribution, as well as cell 
attachment and growth into the interior region of the hydroxyapatite granules (Fig. 4). Cells 
in tissue constructs exhibited growth patterns of enhanced proliferation during the first two 
weeks of cultivation, followed by a decrease in cell numbers.  
 
Fig. 3. Bone tissue engineered graft for the treatment of periodontal intrabony defects, 
macroscopic view of the graft.  
A B 
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Fig. 4. AO growing over the hydroxyapatite granules of the scaffold one week after graft 
formation A: scanning electron microscopy, B: stereomicroscope (cells stained with MTT)  
The osteogenic potential of the cells was tested by observation of the mineralisation capacity 
and analysis of gene expression of three important marker genes for osteogenesis: alkaline 
phoshatase, osteopontin and osteocalcin. Alkaline phosphatase activity was higher at three 
weeks in all cultures in osteogenic medium than in the control medium. Gene expression 
levels exhibited patterns of osteogenic differentiation (Maličev et al., 2008).  
We showed that bone-like constructs with viable cells exhibiting differentiated osteogenic 
phenotype can be prepared by cultivation of AO on  hydroxyapatite granules.  
3.1.2 Engineering bone grafts using Bone Marrow derived Stem Cells (BMSC) 
Bone Marrow derived Stem Cells (BMSC) – also termed mesenchymal stem cells (MSC) or 
multipotent adult progenitor cells (MAPC) – are progenitors of skeletal tissue components 
such as bone, cartilage, muscle, the hematopoiesis-supporting stroma and adipocytes 
(Pittenger et al., 1999; Flanagan et al., 2001). The development of methods for isolation, 
expansion and controlled differentiation of BMSC offers possibilities of using these cells as 
an integral component of various clinical applications of tissue engineering, especially in 
reparative osteogenesis.  
The aim of this study was to engineer bone grafts using BMSC for treating long bone defects 
in patients with pseudoartrosis. 
After harvesting bone marrow from the iliac crest (approx. 30 ml), mononuclear cells were 
separated by gradient centrifugation and seeded in primary culture. Non-adherent cells 
were washed out after 24 hours and adherent cells were expanded and passaged to obtain a 
sufficient number of cells.  
Osteogenic differentiation was carried out in confluent monolayer cultures of the second 
passage, which was confirmed by positive von Kossa staining (calcium deposits) and 
staining for the enhanced presence of alkaline phosphatase (Fig. 5). In addition, higher gene 
expression levels of bone sialoprotein II, osteopontin and BMP2 were determined in BMSC 
after osteogenic differentiation compared to control BMSC. 
Porous TCP granules were used as a scaffold. The cells were seeded directly onto the 
granules to achieve an approximate total of 1 × 106 cells per 1 mL of the tissue engineering 
bone construct. The granules were “glued” by inducing fibrin clot formation with the 
addition of thrombin (Fig. 6). Cell viability in the tissue bone construct was confirmed by 
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MTT staining. Light microscopy examination of the cell-seeded constructs showed a 
uniform distribution of viable cells (Fig. 7). 
 
 
Fig. 5. Second passage of BMSC after 18 days in basal growth medium (A,B) and in 
osteogenic medium (C,D), respectively. The cells were subsequently stained for calcium 
deposits according to von Kossa (A,C) and for alkaline phosphatase (B,D) (photos were 
taken at magnification 100x).  
 
Fig. 6. Preparation of bone implant composed by BMSC after osteogenic differentiation, TCP 
granules and fibrin glue. 
 
Fig. 7. BMSC after osteogenic differentiation and seeding onto the granules of TCP and 
staining with MTT, showing an equal distribution of cells in the graft (stereomicroscope, 
photos were taken at magnification 20x).  
             A                B                     C                  D 
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3.1.3 Engineering bone grafts using Adipose-derived Stem Cells (ASC) in a perfusion 
bioreactor 
ASC are an attractive cell source for autologous bone tissue engineering, due to their easy 
accessibility and abundance, as well as their potential for osteogenic differentiation (Zuk et 
al., 2001). In combination with scaffolds with mechanical properties similar to native bone, 
they could enable engineering of bone grafts for treating load-bearing sites.  
The aim of this study was to engineer bone grafts using ASC on decellularized bone 
scaffolds and to evaluate the effects of long term perfusion culture conditions (enabling 
efficient cell nutrition and gas exchange) on the quality (cell distribution and bone matrix 
formation) of bone grafts. Perfusion culture has already been proved to be beneficial for 
BMSC based grafts in terms of cell distribution and bone matrix deposition (Gomes et al., 
2003; Grayson et al., 2008). 
Human ASC were isolated from lipoaspirates of three different donors, characterized and 
expanded up to the 3rd passage. The osteogenic potential of ASC was tested using von Kossa 
and Alizarin Red staining. For the perfusion study, cells were seeded on decellularized 
bovine trabecular bone scaffolds (4 mm   4 mm) and subsequently cultured in two 
different medias (control and osteogenic), in static culture and perfusion bioreactors (Fig. 9). 
Four experimental groups were formed: (i) control-static, (ii) control-perfused, (iii) osteo-
static and (iv) osteo-perfused. After 5 weeks, constructs were evaluated for cell viability 
(live/dead assay), DNA content (PicoGreen), cell distribution (4'-6-diamidino-2-
phenylindole - DAPI), collagen (Trichrome), osteopontin and sialoprotein 
(immunohistochemistry).  
ASC from three different donors showed that osteogenic culture conditions resulted in 
strong mineral deposition, as confirmed by von Kossa and Alizarin Red staining. 
Additionally, these data show a significant donor-to-donor variability in the osteogenesis of 
ASC (Fig 8). 
During cultivation of ASC grafts, the DNA content increased in all experimental groups and 
was generally higher under osteogenic than under control conditions. Histological analysis 
demonstrated that grafts cultured in osteogenic medium contained more total collagen, 
bone sialoprotein and osteopontin than matching controls. Additionally, under static culture 
conditions, cell growth and matrix deposition were located mostly at the construct 
periphery, while perfused constructs exhibited a more even cell and matrix distribution 
throughout the scaffold volume (Figs. 10 and 11).  
In summary, a combination of ASC as cell source, decellularized bone as scaffold and 
perfused culture conditions in combination with osteo-inductive supplements, provides a 
promising approach to obtaining high quality tissue engineered bone grafts. Furthermore, 
cultivation of ASC in a perfusion bioreactor improves cell and bone matrix distribution 
within the graft and therefore assures a superior cultivation environment to static culture, 
especially for larger grafts and for longer periods of time. However, for the successful 
application of ASC based bone grafts in clinical settings, the donor-to-donor variability in 
the osteogenic potential of ASC needs to be considered. (Fröhlich et al., 2010) 
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Fig. 8. Osteogenic potential of ASC. ASC of three donors (B, C, D) were cultured under 
either control or osteogenic medium for various time lengths and were stained with Alizarin 
Red (red) and von Kossa (black). (Fröhlich et al., 2010) 
 
Fig. 9. Perfusion bioreactor used in the study. The region indicated by a white rectangle in A 
is shown schematically in panel B. Medium flows throughout the scaffold, as indicated by 
arrows (B). (Fröhlich et al., 2010) 
 
Fig. 10. Long term cultivation of ASC grafts in static and perfused culture. Live/dead 
staining of the central part of the cultured grafts under perfused (A) and static (B) 
conditions. Collagen (C, D) (blue) and osteopontin (E, F) (brown) deposition within the 
scaffold is more abundant and more uniformly distributed under perfused conditions (C, E) 
than under static culture (D, F). The scale bar is 0.5 mm. (Fröhlich et al., 2010) 
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Fig. 11. Cell distribution within the ASC bone grafts. Constructs were stained with DAPI to 
visualize cell distribution (cell nuclei shown in white). Seeding resulted in an even initial 
distribution of cells throughout the scaffold (A). After 5 weeks of static culture, cells were 
found mostly in the outer regions of the constructs (indicated by arrows) (B). After 5 weeks 
of culture with medium perfusion, cells were more evenly distributed throughout the 
construct volume (indicated by arrows) (C). The scale bar is 0.5mm. (Fröhlich et al., 2010) 
3.2 Vascularization of tissue engineered bone grafts 
Vascularization is of critical importance for the integration and survival of larger engineered 
bone grafts on implantation, since it ensures efficient gas and nutrition exchange with all 
cells within the tissue.  
There are several approaches being utilized in order to vascularize bone grafts, and 
generally one or a combination of three major principles can be followed (Fig. 12). In vivo 
pre-vascularization employs the implantation of the bone grafts into environments rich in 
vascular supply (subcutaneous, intramuscular or intraperitoneal sites), where the constructs 
can be invaded with new vascular networks at their surfaces. However, transplantation to 
the site of interest is impossible without damaging the initial vascular network.  
Vascularization of an implanted graft can also be accelerated by the utilization of angiogenic 
factors. Growth factors, such as VEGF, PDGF and FGF, play a crucial role in angiogenesis 
(Jain et al., 2003). Incorporation of these factors into scaffolds and control of their local 
release rate and delivery regime is one possibility for accelerating vascular in-growth in vivo. 
Another way of achieving vascularization of tissue engineered bone grafts is co-culturing 
endothelial and osteogenic cells into bone constructs engineered in vitro – the so called in 
vitro prevascularization approach. Endothelial cells have the potential to form new vessels 
within the scaffolds, with the potential to anastomose with the host vasculature when 
implanted in vivo. Moreover, endothelial cells not only contribute to forming the vasculature 
to deliver nutrients to the bone but are also important in terms of interaction with and 
differentiation of osteoprogenitor cells (Rouwkema et al., 2006; Unger et al., 2007). Adult 
endothelial cells can be used as a source of endothelial cells, but recently, adult 
mesenchymal stem cells have also been shown to have the potential to differentiate toward 
the endothelial lineage (Miranville et al., 2004; Valarmathi et al., 2008). (Reviewed in 
Fröhlich et al., 2008).  
In addition to endothelial cells, smooth muscle cells or pericytes are also necessary for 
forming a functional vasculature. We exploited the vasculogenic potential of ASC and 
showed that ASC spontaneously, as well as in induced cultures, formed up to 1 mm long 
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endothelial structures. In the same manner, ASC had the potential for smooth muscle 
phenotype (Fig. 13). (Fröhlich et al., 2009) Since they have all the necessary types of cells - 
osteogenic (Fig. 8, Fig. 9) and vascular (Fig. 13), ASC seem to be an ideal source of cells for 
engineering autologous vascularized bone grafts. However, optimal culture conditions for 
the co-existence of various cell types still need to be determined.   
BMSC have also been tested for their smooth muscle and endothelial phenotype. BMSC 
expressed α  smooth- muscle actin characteristic of smooth muscle cells (Fig. 14), but did not 
form endothelial structures, as seen with ASC (data not shown).   
 
 
 
 
 
 
 
 
Fig. 12. Approaches to vascularizing engineered bone scaffolds.  Left: The arterio-venous 
(AV) loop as an example of an in vivo approach for pre-vascularizing scaffolds.  Center: One 
cell-free approach is to immobilize angiogenic growth factors (AGF) and osteogenic growth 
factors (OGF) in scaffolds and directly implant into the site of interest.  In this method, the 
growth-factors induce migration of angiogenic and osteo-progenitor cells and provide them 
with the stimuli for neo-vessel formation and osteogenic differentiation.  Right: The cell-
based, tissue-engineering approach utilizes osteogenic cells (OC) and endothelial cells (EC) 
in a three-dimensional co-culture. (Fröhlich et al., 2008)   
www.intechopen.com
 
Bone Regeneration 
 
48
 
Fig. 13. ASC as a cell source for vascularization of bone constructs. ASC formed up to 1 mm 
long CD31 positive endothelial structures (green) with the close proximity of surrounding 
cells (blue stained nuclei) when cultured in stromal (control) medium (A). ASC also formed 
endothelial structures in endothelial medium but the structures were less numerous and 
without the specific pattern of surrounding cells (B). After induction with smooth muscle 
medium, the number of α smooth-muscle actin positive cells (green) increased (D) in 
comparison to the control medium (C). The scale bar is 200 µm. (Fröhlich et al., 2009) 
 
 
Fig. 14. BMSC of 3rd passage were induced to differentiate into the smooth muscle 
phenotype. Positive staining for α smooth-muscle actin was evident in the control medium 
(A) and was further enhanced by exposing the cells to induction medium (B). The scale bar is 
200 µm. 
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3.3 Clinical projects for bone regeneration 
The first concept (Section 3.1.1.) -  employing osteoblasts of cancellous alveolar bone loaded 
onto the HA granules - has been developed to treat periodontal diseases (BoneArtTM-A). The 
second approach (Section 3.1.2.) - employing bone marrow derived mesenchymal stem cells 
(BMSCs) differentiated into osteoblasts and loaded onto the TCP granules - has been 
developed to treat long bone defects (BoneArtTM-S). In both cases, the principle is similar 
(Fig. 15): cells are isolated and proliferated from autologous tissue harvested from patients. 
Using a criopreservation step, we can adapt to the time of predicted implantation. When 
cells are proliferated to the desired number, they are seeded on scaffold material. Induction 
of differentiation can be added to the protocol before or after bone graft preparation. The 
bone graft can either be implanted immediately or submitted to conditions that stimulate 
osteogenesis prior to implantation. Grafts need to be tested according to the quality control 
(QC) protocol, ensuring the safety and efficiency of the product. 
 
Fig. 15. Principle of bone tissue engineering for clinical application.    
3.3.1 Autologous Alveolar Osteoblasts (AO) for the treatment of paradontosis  
Periodontal diseases (periodontitis) is a chronic, infectious, inflammatory disease that affects 
the dental attachment apparatus  - i.e. the tissues that support and anchor the teeth to the 
jaw; these include the cementum, periodontal ligament ans alveolar bone. If left untreated, 
periodontal disease may result in complete destruction of the alveolar bone as well as the 
othe supporting tissues.  (Lin et al., 2008).  
The possibility of enhancing bone regeneration by implanting alveolar osteoblasts (AO) in 
combination with an appropriate scaffold is of clinical interest, particularly in reconstructive 
maxillofacial surgery and periodontology (Lin et al., 2008). In the research project, the 
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concept was tested that artificial matrices, seeded with cells of osteogenic potential, may be 
implanted into sites where osseous damage has occurred, which could lead to significant 
osseous regeneration.  
Firstly, the growth and differentiation of alveolar bone cells in tissue-engineered constructs 
and in monolayer cultures, as a basis for developing procedures for routine preparation of 
bone-like tissue constructs, were compared (Maličev et al., 2008).  
Autologous constructs as described above (Section 3.1.1) were prepared to treat six patients 
with aggressive periodontitis by an implantation of a cell-based alkaline phosphatase 
approach. The operative implantation procedures were carried out without any 
complications and no side effects were detected that could be assigned to the tissue 
engineered construct. The newly forming bone is clearly seen in X-rays 3 months after 
implantation (Fig. 16). Clinical evaluation at 6 months and 12 months after implantation 
showed a significantly higher gain of clinical attachment in cases in which cellularized grafts 
were implanted in comparison with the control group (implantation of the scaffold alone) 
(Fig. 17).  
 
 
 
 
 
Fig. 16. X-ray of implanted site before and 3 months after treatment. Arrows indicate the 
limit of bone tissue. 
In the first observation period after implantation, there was a significantly higher gain of 
clinical attachment in sites at which cells were added, compared to sites at which only 
material was implanted, while no difference is observed in the second period. Overall, in 
cases in which cells were implanted together with biomaterial, the bone regeneration 
process was faster and more efficient. 
This clinical project confirmed the positive effect of autologous cell therapy for bone 
regeneration.  
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Fig. 17. Gain of clinical attachment measured up to 6 months after implantation (GCAL 0-6) 
and gain of clinical attachment in the period from first measurement to second 
measurement up to 18 months after implantation.  
3.3.2 Autologous Bone Mesenchymal Stem Cells (BMSC) for the treatment of large 
long bone defects  
A project to evaluate the concept of bone tissue engineering for the treatment of severe long 
bone defects was carried out using autologous BMSC differentiated into osteoblasts as a cell 
source and a TCP scaffold in combination with fibrin glue (Figs. 5-7). The bone marrow was 
harvested from the patient’s posterior iliac crest. BMSC were isolated and expanded to the 
desired number according to Pittinger et al., (1999) with some modifications as described in 
3.1.2 (Krečič Stres et al., 2007). Expanded cells with proven osteogenic potential were loaded 
onto macroporous TCP granules together with fibrin glue, which enabled the formation of 
solid grafts (Fig. 6). An outline of the procedure for the preparation of tissue engineered 
bone graft is shown in Figure 18.  
The tissue engineered bone construct was surgically implanted to fill gaps in the long bone 
of patients, mainly for the treatment of pseudoarthrosis in the femur or tibia. 
Six patients with a history of multiple failing surgical revisions were treated according to the 
described procedure (Fig. 19A). None of the patients had any side affects connected with the 
treatment procedure. Preliminary results were promising since they suggested ossification 
of the bone defects on X-ray (Fig. 19 B,C). Scintigraphy (99mTc DPD) also showed evident 
perfusion and osteoblast activity in the implanted site. At the intermediate observation (5-14 
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Fig. 18. An outline of the procedure for the preparation of tissue engineered bone graft 
BoneArtTM for long bone defect treatment from autologous BMSC as carried out in Educell 
Ltd. 
months after implantation), bone bridging or callus formation was observed in 4 out of 6 
patients and 3 patients were allowed full weight bearing of the treated leg. 
However, the final evaluation of the clinical outcome did not show the expected results. 
Factors that probably contributed to the failure of these treatments were: 
- the extensive volume of the missing tissue (up to 50 ml), which hindered perfusion of 
the graft as it was designed 
- damaged/inadequate surrounding tissue (fibrotic tissue after burns…) 
- septic events prior to cell implantation 
Due to the small number of patients included in our study, as well as their clinical history, 
we cannot reach general conclusions about how useful a cell based treatment approach 
could be in the treatment of non-unions.   
Several clinical reports do show successful results of implantation of tissue engineering bone 
tissues although, especially in large defects, in which a tissue engineering approach is 
expected to help after other treatments have failed, probably more advanced treatment 
concepts, considering also perfusion and vascularisation of the tissue, should be developed.  
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A B C 
Fig. 19. Clinical application of tissue engineered bone graft. A: implantation of the graft, B: 
X-ray immediately after implantation, granulation of the TCP in a graft is visible, C: X-ray 6 
months after implantation, the formation of new bone can be observed on the proximal part 
of the tibia, however complete bone filling was not achieved and a defect remained on the 
distal part of the non-union 
4. Conclusion  
Despite the high regeneration capacity of bone tissue, surgical procedures used in reparative 
osteogenesis do not consistantly result in structural and functional recovery. This state is 
associated with the disintegration or insufficiency of cambial cells in bone tissue and 
osteogenic deficiency. Cell based therapies are a new therapeutic approaches in regenerative 
medicine and using autologous cells is a promising strategy for bone regeneration. 
We tested the three of the most studied and relevant sources of osteogenic cells: osteoblasts 
(from alveolar bone), bone marrow derived stem cells (BMSC) and adipose derived stem 
cells (ASC). We showed that all three cell sources posses adequate proliferation capacity for 
potential tissue engineering applications and their differentiation capacity was also proven 
by testing mineralisation of the extracellular matrix as well as gene expression, specific for 
osteogenic differentiation.  
However, clinical application of a tissue engineering approach is not reflecting the 
enormous effort in research and preclinical development that has been invested so far - 
there is still a severe, unmet need for technologies that will facilitate bone tissue 
regeneration.  
Our clinical projects indicate a positive effect of cell based therapies for the treatment of 
bone defects; in the case of alveolar bone tissue as well as in the case of long bone defects. 
However, there are limitations in the technology, especially in the treatment of large defects. 
Extensive research on tissue vascularization might help cell and tissue engineering 
technologies become more prospective in bone regeneration. From this aspect, the vascular 
potential of mesenchymal stem cells seems to indicate a promising area for further bone 
tissue vascularization research. 
Although basic research on osteogenic differentiation potentials of stem and other 
osteogenic cells  is crucial for understanding the bone tissue engineering area, and promises 
great potential for its use in clinics, only experience from clinical applications will give 
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relevant information and final answers regarding the usefulness of cell and tissue 
engineered products for various clinical indications.  
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